Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT00621556 · Massachusetts General Hospital · PHASE1 · terminated · last registry update 2009-01-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor patient enrollment due to logistical issues” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2009-01-29Also stopped (terminated): Massachusetts General Hospital, RG1068 (Synthetic Human Secretin) (NCT00621283)
- 2009-01-29Also stopped (terminated): Massachusetts General Hospital, RG1068 (Synthetic Human Secretin) (NCT00620919)
- 2008-04-17Phase 3 first posted: Repligen Corporation, RG1068 (synthetic human secretin) (NCT00660335)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision